Venus Medtech (China)

Hangzhou Qiming Medical Device Co., Ltd. ("Venus Medtech") is a Chinese transcatheter heart valve medical device company. It was founded in 2009 and is headquartered in the Hangzhou National High-Tech Industrial Development Zone (Binjiang). It listed on the Main Board of the Hong Kong Stock Exchange on 10 December 2019 under stock code 02500. The company states it has established a comprehensive structural heart disease solution covering aortic, pulmonary, mitral and tricuspid valve diseases as well as surgical accessory products, and that its "Made in China" valve products have reached more than 60 countries and regions globally.

Venus Medtech was founded in 2009 and is headquartered in the Hangzhou National High-Tech Industrial Development Zone (Binjiang). In 2014, the company won the national championship in the biopharmaceutical industry with its "novel biological heart aortic valve project." On 10 December 2019, it listed on the Main Board of the Hong Kong Stock Exchange under stock code 02500. In 2017, VenusA-Valve became the first TAVR product approved for marketing in China, filling a gap in domestic transcatheter valve therapy. The company states it has established global R&D centers in China, the United States and Israel, and has nearly 700 employees from nearly 10 countries.

• 2023

  VenusP-Valve received FDA approval for an Investigational Device Exemption (IDE), becoming the first Chinese-made artificial heart valve approved for clinical research in the US. The next-generation dry-tissue TAVR product Venus-PowerX was also approved in Argentina and Chile.

• 2019

  Venus Medtech listed on the Main Board of the Hong Kong Stock Exchange on December 10, with stock code 02500.

• 2017

  VenusA-Valve became the first TAVR product approved for marketing in China, filling the gap in domestic transcatheter valve therapy.

• 2014

  The company won the national championship in the biopharmaceutical industry for its 'new biological heart aortic valve project'.

• 2009

  Venus Medtech was founded in Hangzhou, China.

China's leading transcatheter heart valve medical device enterprise, aiming to become a global leader in the structural heart disease field.

• VenusA-Valve

  TAVR product; first TAVR product approved for marketing in China (2017).

• VenusP-Valve

  Self-expanding TPVR product approved in China and Europe; approved in nearly 70 countries or regions; received FDA IDE approval in 2023.

• Cardiovalve

  Innovative device usable for both TMVR and TTVR; completed enrollment in TARGET study and submitted EU CE certification application.

• Venus-PowerX

  New-generation dry valve TAVR product; approved in Argentina and Chile in 2023.

• 2023

  Founder unauthorized borrowing and related-party fund flows; stock plunges nearly 70% on resumption after 15-month suspension

  Venus Medtech, the “first heart valve stock,” suspended trading in November 2023. Former chairman Zeng Min and former general manager Zi Zhenjun borrowed from the company without authorization, with maximum outstanding amounts totaling about RMB 630 million; the investigation also found about RMB 1.85 billion in related-party transfers and deposit pledge guarantees, among other things; both resigned. On the first trading day after resumption in March 2025, the share price fell more than 65%; Zi Zhenjun later faced another whistleblower report. The funds were returned with principal and interest, and management was replaced; no regulatory penalty conclusion has been seen.

  Source

Read more

• 2021.12.08

  Reported2021.12.09

  Venus Medtech acquires Cardiovalve[9]Venus Medtech收购Cardiovalveen.people.cn

  Venus Medtech acquired Israeli company Cardiovalve for $300 million, according to a joint statement by the two companies. The stated purpose was to expand Venus Medtech's valve-replacement product portfolio and accelerate innovation and internationalization.

• 2021.12.07

  Reported2021.12.08

  Venus Medtech announces acquisition of Cardiovalve[10]Venus Medtech宣布收购Cardiovalvenewswire.ca

  Venus Medtech announced that it would acquire 100% of Cardiovalve's equity for $300 million, with payment in installments subject to agreed milestones.

Read more

1. 1启明医疗-杭州启明医疗器械股份有限公司是中国领先的经导管心脏瓣膜医疗器械企业。venusmedtech.com
2. 2公司简介-启明医疗-杭州启明医疗器械股份有限公司是中国领先的经导管心脏瓣膜医疗器械企业。venusmedtech.com
3. 3隐私声明-启明医疗-杭州启明医疗器械股份有限公司是中国领先的经导管心脏瓣膜医疗器械企业。venusmedtech.com
4. 4Cookie 声明-启明医疗-杭州启明医疗器械股份有限公司是中国领先的经导管心脏瓣膜医疗器械企业。venusmedtech.com
5. 5Venus Medtech (China)wikidata.org
6. 6Founder unauthorized borrowing and related-party fund flows; stock plunges nearly 70% on resumption after 15-month suspensionnews.qq.com
7. 7Founder unauthorized borrowing and related-party fund flows; stock plunges nearly 70% on resumption after 15-month suspensionnews.qq.com
8. 8Founder unauthorized borrowing and related-party fund flows; stock plunges nearly 70% on resumption after 15-month suspensionjiemian.com
9. 9Venus Medtech收购Cardiovalveen.people.cn
10. 10Venus Medtech宣布收购Cardiovalvenewswire.ca